Filtered By:
Drug: Enbrel
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 39 results found since Jan 2013.
Effect of Inflammation on the Process of Stroke Rehabilitation and Poststroke Depression
Conclusions
Stroke comprises ischemic stroke and ICH. The immuno-inflammatory process is involved in neural plasticity following events such as a hemorrhage or ischemic stroke. After ischemia, astrocytes, microglia, and MDMs play important roles during rehabilitation with the modulation of cytokines or chemokines, such as TNF-α and IL-1. Moreover, MiRNAs are also important posttranscriptional regulators in these glial mitochondrial responses to cerebral ischemia. ICH involves processes similar and different to those seen in ischemia, including neuronal injury, astrocytic and microglial/macrophage activation, and n...
Source: Frontiers in Psychiatry - April 10, 2019 Category: Psychiatry Source Type: research
Reversible Cerebral Vasoconstriction Syndrome after Administering Etanercept during Puerperium
Our objective is to clarify relationship between reversible cerebral vasoconstriction syndrome and administrating etanercept during puerperium. Several lines of evidence have suggested tumor necrosis factor (TNF) as a mediator of vascular dysfunction associated with estrogen deficiency. A 32-year-old woman resumed etanercept (25 mg/week), a TNF inhibitor, which had been discontinued during pregnancy, because of the deterioration of rheumatoid arthritis. She was admitted to our hospital with upper right quadrant blindness and mild right hemiparesis accompanied by pulsating left occipital pain, which had appeared 4 hours aft...
Source: Journal of Stroke and Cerebrovascular Diseases - January 9, 2019 Category: Neurology Authors: Daisuke Hara, Saki Nukui, Takahiro Shimizu, Hisanao Akiyama, Yasuhiro Hasegawa Tags: Case Report Source Type: research
Finding Good Candidates for Risk-Sharing Arrangements
Continued from Part I that discusses the tools device manufacturers can use to manage risk
How to find good candidates?
Not all devices are created equal. But how can device manufacturers identify the low-hanging fruit for a risk-sharing arrangement? Needless to say, the more characteristics a product has that are associated with successful risk-sharing arrangements, the more such an arrangement is likely to succeed.
To illustrate, in Exhibit 1, we chart a select number of risk-sharing arrangements established since 2015 along two key dimensions: product effectiveness and time needed to observe expected outcomes. The findi...
Source: MDDI - April 3, 2018 Category: Medical Devices Authors: Harry Liu and Christine Chen Tags: Contract Manufacturing Design Source Type: news
Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept.
CONCLUSIONS: RA patients with TCZ do not have a medium-term excess of CV risk in patients compared with ETN.
PMID: 29303702 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - January 6, 2018 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
CONCLUSION: Based on data accumulated to date in PSOLAR, treatment with biologics did not have an impact on the risk of MACE in patients with moderate-to-severe psoriasis. <p><em>J Drugs Dermatol. 2017;16 (10):1002-1013.</em></p>.
PMID: 29036254 [PubMed - in process]
Source: Journal of Drugs in Dermatology - October 18, 2017 Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year.
In 2015, the FDA asked drug makers to strengthen their warning labels.
Since then, most have listed their dangerous side effects on the bottle.
But one manufacturer thought they didn’t have to warn people about their dangerous drug.
They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1
The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche.
...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news
KL 10 Animal models for gestational hypertension
Publication date: July 2017 Source:Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health, Volume 9 Author(s): Christian Delles, Delyth Graham, Hannah L. Morgan, Heather Y. Small, Shona Ritchie The prevalence of cardiovascular diseases and particularly of hypertension is increasing worldwide. Consequently, the number of women with hypertension in pregnancy is also increasing. Several rodent models of hypertension have been characterised in depth but only few models exhibit the complex cardiovascular phenotype that is typically seen in human hypertension. The stroke-prone spontaneously hypertensi...
Source: Pregnancy Hypertension: An International Journal of Womens Cardiovascular Health - August 13, 2017 Category: OBGYN Source Type: research
Saving Vanessa, part 1: A mystery rash, a stroke and an epic rescue
Vanessa’s rash first appeared on her arms and legs when she 3 or 4 months old. It was red and bumpy and went away when she was sick with a virus, which happened often. Then it would come back. The dermatology team she saw at Boston Children’s Hospital was puzzled.
“I was expecting they were going to think it was nothing, but they took it very seriously,” says Katherine Bell, one of Vanessa’s mothers. “They took a biopsy and very quickly realized they had no idea what it was.”
Vanessa’s case was even featured at a regional dermatology conference where doctors take up mystery patients. “A hundred to 150 der...
Source: Thrive, Children's Hospital Boston - July 25, 2017 Category: Pediatrics Authors: Nancy Fliesler Tags: Diseases & Conditions Our Patients’ Stories Dr. Carolyn Rogers Dr. Pui Lee Dr. Robert Sundel Dr. Scellig Stone Dr. Todd Lyons stroke Source Type: news
Role of Tumor Necrosis Factor-{alpha} and Natural Killer Cells in Uterine Artery Function and Pregnancy Outcome in the Stroke-Prone Spontaneously Hypertensive RatNovelty and Significance Pregnancy and Hypertension
Women with chronic hypertension are at increased risk of maternal and fetal morbidity and mortality. We have previously characterized the stroke-prone spontaneously hypertensive rat (SHRSP) as a model of deficient uterine artery function and adverse pregnancy outcome compared with the control Wistar–Kyoto. The activation of the immune system plays a role in hypertension and adverse pregnancy outcome. Therefore, we investigated the role of tumor necrosis factor-α in the SHRSP phenotype in an intervention study using etanercept (0.8 mg/kg SC) at gestational days 0, 6, 12, and 18 in pregnant SHRSP compared with vehicle-tre...
Source: Hypertension - October 11, 2016 Category: Cardiology Authors: Small, H. Y., Nosalski, R., Morgan, H., Beattie, E., Guzik, T. J., Graham, D., Delles, C. Tags: Animal Models of Human Disease, Basic Science Research, Inflammation, Hypertension, Preeclampsia Original Articles Source Type: research
Practice advisory: Etanercept for poststroke disability: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
Conclusions:
For patients with poststroke disability, the evidence is insufficient to support or refute a benefit of etanercept for the treatment of poststroke disability.
Recommendations:
Clinicians should counsel patients considering etanercept for treatment of poststroke disability that the evidence is insufficient to determine the treatment's effectiveness and that it may be associated with adverse outcomes and high cost (Level U).
Source: Neurology - June 5, 2016 Category: Neurology Authors: Gronseth, G. S., Messe, S. R. Tags: All Cerebrovascular disease/Stroke, All Rehabilitation SPECIAL ARTICLE Source Type: research
Therapeutically Targeting Tumor Necrosis Factor-{alpha}/Sphingosine-1-Phosphate Signaling Corrects Myogenic Reactivity in Subarachnoid Hemorrhage Basic Sciences
Conclusions—
Vascular smooth muscle cell TNFα and sphingosine-1-phosphate signaling significantly enhance cerebral artery tone in SAH; anti-TNFα and anti–sphingosine-1-phosphate treatment may significantly improve clinical outcome.
Source: Stroke - July 27, 2015 Category: Neurology Authors: Yagi, K., Lidington, D., Wan, H., Fares, J. C., Meissner, A., Sumiyoshi, M., Ai, J., Foltz, W. D., Nedospasov, S. A., Offermanns, S., Nagahiro, S., Macdonald, R. L., Bolz, S.-S. Tags: Animal models of human disease, Acute Cerebral Hemorrhage, Brain Circulation and Metabolism, Other Stroke Treatment - Medical, Other Vascular biology Basic Sciences Source Type: research
Chronic Elevation of Tumor Necrosis Factor-{alpha} Mediates the Impairment of Leptomeningeal Arteriogenesis in db/db Mice Basic Sciences
Conclusions—
These results indicate that leptomeningeal arteriogenesis is impaired in db/db mice and that suppression of the tumor necrosis factor-α response to hypoperfusion is the major contributing factor.
Source: Stroke - May 22, 2015 Category: Neurology Authors: Yukami, T., Yagita, Y., Sugiyama, Y., Oyama, N., Watanabe, A., Sasaki, T., Sakaguchi, M., Mochizuki, H., Kitagawa, K. Tags: Cerebrovascular disease/stroke, Type 2 diabetes, Other Vascular biology Basic Sciences Source Type: research
Drugs used to treat joint and muscle disease
Publication date: Available online 19 February 2015 Source:Anaesthesia & Intensive Care Medicine Author(s): David G. Lambert Joint disease: Arthritis can be simply broken into osteoarthritis and rheumatoid arthritis (RA). Osteoarthritis is treated with symptomatic pain relief and surgery. RA is a chronic autoimmune disease that causes inflammation of joints (leading to their destruction), tissues around joints and other organ systems. Treatment (for pain) of RA in the first instance is with non-steroidal anti-inflammatory drugs, with second-line treatment using disease-modifying antirheumatic drugs (DMARDs). DMAR...
Source: Anaesthesia and intensive care medicine - February 24, 2015 Category: Anesthesiology Source Type: research
Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia
Conclusions:
Our data suggest that XPro1595 and etanercept improve functional outcome after focal cerebral ischemia by altering the peripheral immune response, changing blood and spleen cell populations and decreasing granulocyte infiltration into the brain. Blocking solTNF, using XPro1595, was just as efficient as blocking both solTNF and tmTNF using etanercept. Our findings may have implications for future treatments with anti-TNF drugs in TNF-dependent diseases.
Source: Journal of Neuroinflammation - December 12, 2014 Category: Neurology Authors: Bettina ClausenMatilda DegnNellie MartinYvonne CouchLeena KarimiMaria OrmhøjMaria-Louise MortensenHanne GredalChris GardinerIan SargentDavid SzymkowskiGéraldine PetitTomas DeierborgBente FinsenDaniel AnthonyKate Lambertsen Source Type: research
